AAV Natural Infection Induces Broad Cross-Neutralizing Antibody Responses to Multiple AAV Serotypes in Chimpanzees

Human Gene Therapy Clinical Development

Volumn 27, Issue 2, 2016, Pages 79-82

  Calcedo, Roberto ^a   Wilson, James M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADENO ASSOCIATED VIRUS; ADENOVIRUS INFECTION; ANIMAL EXPERIMENT; ARTICLE; CHIMPANZEE; CONTROLLED STUDY; HEK293 CELL LINE; HUMORAL IMMUNITY; IN VITRO GENE TRANSFER; IN VITRO STUDY; LIMIT OF DETECTION; LONGITUDINAL STUDY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEROCONVERSION; SEROTYPE; VIRUS GENOME; ADMINISTRATION AND DOSAGE; ANIMAL; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETICS; IMMUNOLOGY; PAN TROGLODYTES;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; LONGITUDINAL STUDIES; PAN TROGLODYTES; SEROGROUP;

EID: 85006226955     PISSN: 23248637     EISSN: 23248645     Source Type: Journal    
DOI: 10.1089/humc.2016.048     Document Type: Article

References (26)

1. Lisowski L, Tay SS, Alexander IE. Adenoassociated virus serotypes for gene therapeutics. Curr Opin Pharmacol 2015;24:59-67.
2. Friedman-Einat M, Grossman Z, Mileguir F, et al. Detection of adeno-associated virus type 2 sequences in the human genital tract. J Clin Microbiol 1997;35:71-78.
3. Gao G, Vandenberghe LH, Alvira MR, et al. Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol 2004;78:6381-6388.
4. Shin JH, Yue Y, Smith B, et al. Humoral immunity to AAV-6, 8, and 9 in normal and dystrophic dogs. Hum Gene Ther 2012;23:287-294.
5. Rapti K, Louis-Jeune V, Kohlbrenner E, et al. Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. Mol Ther 2012;20:73-83.
6. Wang L, Calcedo R, Bell P, et al. Impact of preexisting immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. Hum Gene Ther 2011;22:1389-1401.
7. Boutin S, Monteilhet V, Veron P, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: Implications for gene therapy using AAV vectors. Hum Gene Ther 2010;21:704-712.
8. Harrington EA, Sloan JL, Manoli I, et al. Neutralizing antibodies against adeno-associated viral capsids in patients with mut methylmalonic acidemia. Hum Gene Ther 2016;27:345-353.
9. Greenberg B, Butler J, Felker GM, et al. Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure. Gene Ther 2016;23: 313-319.
10. Ling C, Wang Y, Feng YL, et al. Prevalence of neutralizing antibodies against liver-tropic adenoassociated virus serotype vectors in 100 healthy Chinese and its potential relation to body constitutions. J Integr Med 2015;13:341-346.
11. Calcedo R, Franco J, Qin Q, et al. Preexisting neutralizing antibodies to adeno-associated virus capsids in large animals other than monkeys may confound in vivo gene therapy studies. Hum Gene Ther Methods 2015;26:103-105.
12. Calcedo R, Vandenberghe LH, Gao G, et al. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis 2009;199: 381-390.
13. Calcedo R, Morizono H, Wang L, et al. Adenoassociated virus antibody profiles in newborns, children, and adolescents. Clin Vaccine Immunol 2011;18:1586-1588.
14. Gao G, Alvira MR, Somanathan S, et al. Adenoassociated viruses undergo substantial evolution in primates during natural infections. Proc Natl Acad Sci U S A 2003;100:6081-6086.
15. Thwaite R, Pages G, Chillon M, et al. AAVrh. 10 immunogenicity in mice and humans. Relevance of antibody cross-reactivity in human gene therapy. Gene Ther 2015;22:196-201.
16. Liu Q, Huang W, Zhang H, et al. Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: Implications for gene therapy using AAV vectors. Gene Ther 2014;21:732-738.
17. Flotte TR, Trapnell BC, Humphries M, et al. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha1-antitrypsin: Interim results. Hum Gene Ther 2011;22:1239-1247.
18. Brantly ML, Chulay JD, Wang L, et al. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci U S A 2009;106: 16363-16368.
19. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011;365: 2357-2365.
20. Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014;371: 1994-2004.
21. Monahan PE, Sun J, Gui T, et al. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: Preclinical evaluation supporting an ongoing adeno-associated virus clinical trial. Hum Gene Ther 2015; 26:69-81.
22. Ferla R, Claudiani P, Savarese M, et al. Prevalence of anti-adeno-associated virus serotype 8 neutralizing antibodies and arylsulfatase B cross-reactive immunologic material in mucopolysaccharidosis VI patient candidates for a gene therapy trial. Hum Gene Ther 2015;26:145-152.
23. Lock M, Alvira M, Vandenberghe LH, et al. Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. Hum Gene Ther 2010;21:1259-1271.
24. Roy S, Vandenberghe LH, Kryazhimskiy S, et al. Isolation and characterization of adenoviruses persistently shed from the gastrointestinal tract of non-human primates. PLoS Pathogens 2009;5: e1000503.
25. Roy S, Calcedo R, Medina-Jaszek A, et al. Adenoviruses in lymphocytes of the human gastrointestinal tract. PLoS One 2011;6:e24859.
26. Calcedo R, Vandenberghe LH, Roy S, et al. Host immune responses to chronic adenovirus infections in human and nonhuman primates. J Virol 2009;83:2623-2631.